Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Protein translation in synaptic plasticity: mGluR-LTD, Fragile X.

Waung MW, Huber KM.

Curr Opin Neurobiol. 2009 Jun;19(3):319-26. doi: 10.1016/j.conb.2009.03.011. Epub 2009 May 4. Review.

2.

Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models.

Zhang J, Hou L, Klann E, Nelson DL.

J Neurophysiol. 2009 May;101(5):2572-80. doi: 10.1152/jn.90558.2008. Epub 2009 Feb 25.

3.

Understanding PTEN regulation: PIP2, polarity and protein stability.

Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP.

Oncogene. 2008 Sep 18;27(41):5464-76. doi: 10.1038/onc.2008.243. Review.

PMID:
18794881
4.

PTEN signaling in brain: neuropathology and tumorigenesis.

Endersby R, Baker SJ.

Oncogene. 2008 Sep 18;27(41):5416-30. doi: 10.1038/onc.2008.239. Review.

PMID:
18794877
5.

Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation.

Ronesi JA, Huber KM.

J Neurosci. 2008 Jan 9;28(2):543-7. doi: 10.1523/JNEUROSCI.5019-07.2008.

6.

Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR.

Price TJ, Rashid MH, Millecamps M, Sanoja R, Entrena JM, Cervero F.

J Neurosci. 2007 Dec 19;27(51):13958-67.

7.

Kinase signaling pathways as potential targets in the treatment of Parkinson's disease.

Greggio E, Singleton A.

Expert Rev Proteomics. 2007 Dec;4(6):783-92. Review.

PMID:
18067416
8.

The pathophysiology of fragile x syndrome.

Penagarikano O, Mulle JG, Warren ST.

Annu Rev Genomics Hum Genet. 2007;8:109-29. Review.

PMID:
17477822
9.

mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.

Dann SG, Selvaraj A, Thomas G.

Trends Mol Med. 2007 Jun;13(6):252-9. Epub 2007 Apr 23. Review.

PMID:
17452018
10.

Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1.

Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA.

Lancet Neurol. 2007 Jan;6(1):45-55.

PMID:
17166801
11.

Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X.

Loesch DZ, Bui QM, Dissanayake C, Clifford S, Gould E, Bulhak-Paterson D, Tassone F, Taylor AK, Hessl D, Hagerman R, Huggins RM.

Neurosci Biobehav Rev. 2007;31(3):315-26. Epub 2006 Nov 9. Review.

12.

mTOR and cancer: insights into a complex relationship.

Sabatini DM.

Nat Rev Cancer. 2006 Sep;6(9):729-34. Epub 2006 Aug 17. Review.

PMID:
16915295
13.
14.

Transcription, translation and fragile X syndrome.

Garber K, Smith KT, Reines D, Warren ST.

Curr Opin Genet Dev. 2006 Jun;16(3):270-5. Epub 2006 May 2. Review.

PMID:
16647847
15.
16.
17.

Growing roles for the mTOR pathway.

Sarbassov DD, Ali SM, Sabatini DM.

Curr Opin Cell Biol. 2005 Dec;17(6):596-603. Epub 2005 Oct 13. Review.

PMID:
16226444
18.

From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome.

Bagni C, Greenough WT.

Nat Rev Neurosci. 2005 May;6(5):376-87. Review.

PMID:
15861180
19.

Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations.

Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, Eng C.

J Med Genet. 2005 Apr;42(4):318-21.

20.

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM.

Science. 2005 Feb 18;307(5712):1098-101.

Supplemental Content

Support Center